Healthy Aging, Lifestyle Risk Reduction
Conditions
Keywords
Individualised Health, Prediction, Risk Assessment
Brief summary
In a previous study the investigators have developed a novel biological age model. Assessing biological age is the assessment of the present health status and functional capacity/physiological reserve of that person in comparison with people of the same age and sex. The aim of this study is to investigate the utility and validity of this novel biological age model designed for health promotion in real world conditions.
Detailed description
Study design: This is a longitudinal study, where biological age assessment is conducted in the first and final week of an 11-14 week lifestyle intervention course. These courses take place at a Danish folk high school (Ubberup), which is specialized in performing intensive lifestyle interventions targeting a 10% weight loss. The intention is to include 80 adult men and women. Data collection: This will take place at the facilities at Ubberup folk high school, participants being overnight fasted and without having exercised for the previous 24 hours. All analysis will be performed in investigators lab (Xlab) at the Department of Biomedical Sciences, Copenhagen University. When all samples are analysed Biological age will be calculated for each particpant.
Interventions
BEHAVIORALLifestyle intervention
The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
Sponsors
Technical University of Denmark
University of Copenhagen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Participation in a long course at Ubberup folk high school (12-15 weeks) * Age between 18-65 years
Exclusion criteria
* Previous or current cardiovascular disease * Pregnancy * Conditions that prevents from performing a cycle and/or strength tests
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in biological age | week1 and week 14 | a composite score predicting risk of lifestyle related diseases |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in cardiorespiratory capacity | week 1 and week 14 | VO2max maximal oxygen consumption (ml/min/kg |
| Change in strength | week 1 and week 14 | Hand grip, isometric quadriceps and biceps strength (Nm) |
| Change in Sit to Stand test | week 1 and week 14 | Rise and sit from a chair as many times as possible during 1 minute (number og rises) |
| Change in Central obesity | week 1 and week 14 | Waist to hip ratio is measured by dividing waist circumference with hip circumference in cm. |
| Change in body weight | week 1 and week 14 | measured in kilograms |
| Change in body composition | week 1 and week 14 | BMI (kg/m2) is calculated |
| Change in fat mass | week 1 and week 14 | fat mass(g) is assessed by bioimpedance |
| Change in fat percentage | week 1 and week 14 | Fat%, is assessed by bioimpedance |
| Change in Advanced glycation endproducts | week 1 and week 14 | Levels of glycated protein and lipids as a result of exposure of excess sugars advanced glycation endproducts (AGE) measured in the skin |
| Change in Hormones | Week 1 and week 14 | Insulin |
| Change in muscle mass | week 1 and week 14 | muscle mass(g) is assessed by bioimpedance |
| Change in lipid profile | week 1 and week 14 | HighDensityLipoprotein (mmol/L), LowDensityLipoprofile (mmol/L), TriGlycerides (mmol/L), FreeFattyAcids (mmol/L) and Glycerol (mmol/L) is measured in a blood sample. |
| Change in Inflammatory profile | week 1 and week 14 | C-reactive protein mg/L, soluble urokinase plasminogen activating receptor ng/ml, InterLeukin 6 and 8 (pg/mL), tumor necrosis factor (pg/mL), Leptin and Adiponectin (ng/ml) is analysed from blood samples |
| Change in Blood glucose | week 1 and week 14 | HbA1c and fasting glucose (mmol/L) measured from blood sample |
| Change in Respirometry | week 1 and week 14 | forced vital capacity and forced expiratory volume at one second(L) |
| Change in Blood Pressure | week 1 and week 14 | Systolic and Diastolic blood pressure (mmHg) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in Metabolic Syndrome occurrence | week 1 and week 14 | A cluster of 5 risk factors predicting risk of CVD and T2D |
| Change in Framingham Risk Score | week 1 and week 14 | A composite score predicting 10 years risk of future CVD |
Countries
Denmark
Outcome results
None listed